ACRGF:OTC-Acreage Holdings, Inc (USD)

COMMON STOCK | Drug Manufacturers—Specialty & Generic | OTC

Last Closing Price

USD 2.32

Change

0.00 (0.00)%

Market Cap

USD 0.30B

Volume

0.19M

Average Target Price

N/A
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Acreage Holdings, Inc., formerly High Street Capital Partners, is a principal investment firm specializing in cannabis industry. Acreage Holdings, Inc. was founded in 2014 and is based in New York, New York.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-06-01 )

Largest Industry Peers for Drug Manufacturers—Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
TKPHF Takeda Pharmaceutical Company ..

-1.10 (-2.81%)

USD60.69B 146.13 0.15
MKGAF MERCK Kommanditgesellschaft au..

+9.70 (+8.96%)

USD50.67B 29.60 14.43
ESALY Eisai Co., Ltd

+1.12 (+1.44%)

USD22.18B 23.99 0.15
ESALF Eisai Co., Ltd

N/A

USD21.39B 7.02 0.15
SGIOY Shionogi & Co., Ltd

-0.23 (-1.58%)

USD17.68B 14.69 0.08
SGIOF Shionogi & Co., Ltd

-0.03 (-0.05%)

USD17.46B 14.32 0.08
TEVJF Teva Pharmaceutical Industries..

-0.60 (-5.33%)

USD13.60B 483.60 28.36
MTZPY Mitsubishi Tanabe Pharma Corpo..

N/A

USD10.43B 79.00 0.21
SFOSF Shanghai Fosun Pharmaceutical ..

+0.05 (+1.60%)

USD10.33B 17.58 2.24
GNHAF Vifor Pharma AG

N/A

USD10.04B 58.03 18.96

ETFs Containing ACRGF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -61.09% 14% F 9% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -61.09% 14% F 9% F
Trailing 12 Months  
Capital Gain -87.28% 18% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -87.28% 18% F 6% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -19.26% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -19.26% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 32.33% N/A N/A N/A N/A
Risk Adjusted Return -59.57% N/A N/A N/A N/A
Market Capitalization 0.30B 86% B 65% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 0.77 70% C- 65% D
Price / Cash Flow Ratio -4.16 69% D+ 79% C+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -36.59% 54% F 22% F
Return on Invested Capital -2.50% 58% F 33% F
Return on Assets N/A N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 258.06 1% F 1% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.